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Abstract
Background and Aim: Aberrant hypermethylation of cancer-related genes has emerged as a promising strategy for the
development of diagnostic, prognostic and predictive biomarkers in human cancer, including colorectal cancer (CRC). The
aim of this study was to perform a systematic and comprehensive analysis of a panel of CRC-specific genes as potential
diagnostic, prognostic and predictive biomarkers in a large, population-based CRC cohort.
Patients and Methods: Methylation status of the SEPT9, TWIST1, IGFBP3, GAS7, ALX4 and miR137 genes was studied by
quantitative bisulfite pyrosequencing in a population-based cohort of 425 CRC patients.
Results: Methylation levels of all genes analyzed were significantly higher in tumor tissues compared to normal mucosa (p,
0.0001); however, cancer-associated hypermethylation was most frequently observed for miR137 (86.7%) and IGFBP3 (83%)
in CRC patients. Methylation analysis using the combination of these two genes demonstrated greatest accuracy for the
identification of colonic tumors (sensitivity 95.5%; specificity 90.5%). Low levels of IGFBP3 promoter methylation emerged as
an independent risk factor for predicting poor disease free survival in stage II and III CRC patients (HR = 0.49, 95% CI: 0.28–
0.85, p = 0.01). Our results also suggest that stage II & III CRC patients with high levels of IGFBP3 methylation do not benefit
from adjuvant 5FU-based chemotherapy.
Conclusion: By analyzing a large, population-based CRC cohort, we demonstrate the potential clinical significance of
miR137 and IGFBP3 hypermethylation as promising diagnostic biomarkers in CRC. Our data also revealed that IGFBP3
hypermethylation may serve as an independent prognostic and predictive biomarker in stage II and III CRC patients.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers in
Western countries, and is the second leading cause of cancer-
related deaths in adults [1]. Accumulating evidence indicates that
epigenetic changes play an essential role in the pathogenesis of
CRC. Aberrant DNA methylation represents one of the most
studied epigenetic alteration, and it is well understood that tumor
suppressor genes are frequently silenced by methylation of CpG
islands which commonly reside in the 59 regions of approximately
half of all human genes [2,3,4]. Transcriptional silencing of tumor
suppressor genes has emerged as an important step in the step-wise
process of colorectal carcinogenesis. Epigenetic alterations, par-
ticularly DNA hypermethylation, can be used for the early
detection of premalignant lesions, including adenomatous polyps
in the colon, and is present in the non-neoplastic tissues adjacent
to adenomatous polyps and cancers in the colon [5,6]. In addition
to their use as diagnostic biomarkers, epigenetic changes show
promise as determinants of cancer prognosis, as well as biomarkers
for response to specific chemotherapies [7,8].
In CRC, systematic genome-wide approaches have identified
several genes that show tumor-specific promoter hypermethylation
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that can potentially be developed into clinically relevant diagnos-
tic, prognostic and predictive biomarkers. In the context of CRC,
several such biomarkers have recently been described as poten-
tially promising diagnostic biomarkers, including: SEPT9 (Septin
9), a member of the septin family involved in cytokinesis and cell
cycle control [9,10,11]; ALX4 (Homeobox protein aristaless-like
4), a transcription factor involved in skull and limb development
[12,13]; TWIST1 (Twist homolog 1), an antiapoptotic and pro-
metastatic transcription factor [14,15]; IGFBP3 (Insulin-like
grown factor binding protein 3), a member of the insulin-like
growth factor binding protein family [16]; GAS7 (growth arrest-
specific 7), which plays a putative role in neuronal development
[17,18]; and miR137, a non-coding microRNA which is
embedded in a CpG island [17,19,20,21]. However, to date,
none of these methylation markers have undergone a systematic
validation in a large cohort of CRC patients to fully ascertain their
potential as clinically useful diagnostic, prognostic or predictive
biomarkers. For this reason, we aimed at exploring the diagnostic,
prognostic and predictive value of SEPT9, TWIST1, ALX4,
IGFBP3, GAS7, and miR137 promoter hypermethylation in a
large, well-characterized, population-based CRC cohort. Further-
more, we examined associations between the methylation status of
individual markers and their combination with the clinicopatho-
logical features in these primary CRCs, and for the first time
report that IGFBP3 hypermethylation is a promising diagnostic
and predictive biomarker in CRC patients.
Material and Methods
Patients
This study included 425 CRC patients that were enrolled as
part of the Epicolon-I project, which is a population-based trial of
CRC as described previously [22,23,24]. Since this study aimed to
determine the prognostic and predictive potential of methylation
biomarkers, the patient specimens included in this study were
randomly selected from a previously described cohort of patients
for whom follow-up data were available [7,25,26]. Demographic,
clinical, and tumor-related characteristics of probands, as well as a
detailed family history, were obtained using a previously estab-
lished questionnaire [22]. Clinicopathological and molecular
features of patients included in those studies are described in
Table S1. The study was approved by the ethics committee of all
participating hospitals in the EPICOLON cohort (Hospital 12 de
Octubre, Madrid; Hospital Clinic, Barcelona; Hospital Clı´nico
Universitario, Zaragoza; Hospital Cristal-Pinor, Complexo Hos-
pitalario de Ourense; Parc de Salut Mar, Barcelona; Hospital
Donostia, CIBERehd, University of Country Basque, San
Sebastian; Hospital General Universitario de Alicante; Hospital
General de Granollers; Hospital General de Vic; Hospital General
Universitario de Guadalajara and Fundacio´n para la Formacio´n e
Investigacio´n Sanitarias Murcia; Hospital General Universitario
de Valencia), and written informed consent was obtained from
each patient. The promoter methylation status of six genes
(SEPT9, TWIST1, IGFBP3, GAS7, ALX4 and miR-137) was
analyzed in all 425 CRC patients, as well as in normal colonic
mucosa from 21 healthy individuals with a normal colonoscopy.
Figure 1. Comparison between levels of methylation in primary tumors vs. normal colonic mucosa. Bisulfite pyrosequencing results for
methylation of SEPT9 (A), TWIST1 (B), IGFBP3 (C), ALX4 (D), GAS7 (E) and miR137 (F) genes comparing normal mucosa from healthy controls (N–N) and
primary tumors from CRC patients.
doi:10.1371/journal.pone.0104285.g001
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DNA extraction and bisulfite modification
Genomic DNA was extracted from paraffin-embedded tumor
tissue (FFPE) specimens in the Epicolon-I study. Under supervi-
sion of the study pathologist, tissue sections were carefully
examined, tumor-enriched regions identified and carefully dissect-
ed for DNA extraction. Following paraffin removal by xylene,
DNA was isolated using QiaAmp DNA Mini kits, as per the
manufacturer’s instructions (Qiagen, Valencia, CA). The resultant
genomic DNA was modified with sodium-bisulfite using the EZ
Methylation Gold Kit (Zymo Research, Orange, CA).
DNA Methylation analysis
Bisulfite pyrosequencing was performed for quantitative meth-
ylation analysis as previously described (Figure S1) [7,25,26].
Figure 2. Levels of methylation in normal colonic mucosa and crc tumors from all tnm stage patients. Bisulfite pyrosequencing results of
methylation of sept9 (a), twist1 (b), igfbp3 (c), alx4 (d), gas7 (e) and mir137 (f) comparing normal mucosa from healthy patients (n-n) and primary
tumors from crc patients of all tnm stages i–iv. n (number of subjects); median of methylation (%).
doi:10.1371/journal.pone.0104285.g002
Table 1. Performance Characteristics Of Methylation Markers For The Identification Of Colorectal Cancer.
Gene(s) Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
SEPT9 70.5 95.2 99.6 16.4 65.8
TWIST1 75.6 93.8 99.6 14.7 69.3
IGFBP3 83.0 100.0 100.0 26.3 83.0
GAS7 42.9 94.4 99.4 7.3 37.3
ALX4 61.1 100.0 100.0 13.4 61.6
miR137 87.8 90.5 99.3 31.1 78.3
miR137+IGFBP3 95.5 90.5 99.3 59.4 86.0
TWIST1+IGFBP3 92.2 90.5 99.3 45.2 82.7
TWIST1+miR137 92.8 85.7 98.9 45.0 78.5
miR137+IGFBP3+TWIST1 98.7 93.3 99.3 87.5 92.0
PPV, Positive Predictive Value; NPV, Negative Predictive Value.
doi:10.1371/journal.pone.0104285.t001
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Primers used were designed using the PyroMark 1.0 design
software, and pyrosequencing assays were run on the bisulfite-
modified DNA (Table S2 and Information S1). Mean
percentage methylation for all the CpG sites in each assay was
calculated for each gene/marker. Methylation cut-off values were
determined for each marker based on the average methylation
levels observed in normal colonic mucosa from healthy individuals
+2 standard deviations. Additional confirmatory methylation
analysis for IGFBP3 was also undertaken by a quantitative MSP
(qMSP) assay for the promoter/exon1 CpG island using the
primers and PCR conditions as previously described [27].
CpG Island Methylator Phenotype (CIMP) and
Microsatellite Instability (MSI) status
The CIMP status of the CRC samples from the Epicolon-I
cohort was previously determined using bisulfite pyrosequencing
of the CIMP markers CACNAG1, SOCS1, RUNX3, NEUROG1,
and MLH1, as reported previously [7]. A CRC was considered
CIMP-positive if at least 3/5 promoters were methylated [7].
Microsatellite instability (MSI) testing was performed using
BAT26 and NR24 quasimonomorphic markers as previously
described [28]. Tumors were classified as MSI-positive when
either marker was mutated, and were deemed microsatellite stable
(MSS) when neither marker demonstrated any evidence for
genetic instability.
BRAF mutation
Presence of the V600E BRAF mutation in CRC samples was
detected using TaqMan probes and an ABI Prism 7500 sequence
detection system (Applied Biosystems, Foster City, CA), with allelic
discrimination, as previously described [29].
Statistical Analysis
Continuous variables are reported as mean + standard deviation
(SD), while categorical variables are cited as frequency or
percentages. Statistical differences of baseline characteristics
between groups were analyzed using the x2 test for categorical
data, followed by application of Yates’ correction and the Mann-
Whitney U test for quantitative data analysis. The primary
outcomes of this study were overall survival (OS) and disease-free
survival (DFS). Analyses of both outcomes were performed for the
entire CRC cohort, and separately in the subset of stage II and III
CRC patients in order to specifically evaluate the effect of
methylation status on the prognosis and response to adjuvant
chemotherapy. OS was defined as the time from enrollment to
death, and DFS was defined as the time from enrollment to death
from any cause or the first relapse. Data on OS and DFS were
censored at 1100 days from the date of cancer diagnosis. CRC
tumors were categorized into high and low methylation status
groups using Receiver Operating Characteristics curve (ROC)
analysis. Kaplan-Meier analysis was performed to estimate the
distributions of DFS and OS in stage II and III patients. Survival
distributions were compared using the log rank test. A multivariate
analysis for determination of hazard ratios for death or tumor
recurrence was performed using several variables, including,
lymph node metastasis, TNM stage, MMR status, tumor
differentiation grade, age and adjuvant chemotherapy. Further
analyses were performed using Cox’s proportional hazards
regression in a stepwise manner to test the effect of methylation
status of a given gene/marker with DFS and its interaction with
chemotherapy. Hazard ratios and 95% confidence interval (95%
CI) for death were computed using Cox survival modeling. All
reported p values are two sided, and p values ,0.05 were
considered significant. All calculations were performed using SPSS
10.0 or GraphPad Prism 4.0 statistical software.
Figure 3. Correlation between primary tumor methylation and age of the crc patients. linear regression analysis comparing tumor
methylation of sept9 (a), twist1 (b), igfbp3 (c), alx4 (d), gas7 (e) and mir137 (f) vs age of crc patients (years).
doi:10.1371/journal.pone.0104285.g003
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Results
In our series of 425 CRC cases, the mean 6 SD age of the
patients was 70.4 +211 years, and there were more male patients
than females (252/425; 60.3%). Of the 425 tumors, 117 (27.9%)
were located in the proximal colon, 151 (36.2%) were in the distal
colon, and 150 (35.9%) were located in the rectum. Approximately
12.8% of the cases were stage I, 33.7% stage II, 39.7% stage III,
and 13.7% stage IV tumors. We found that 35/425 (8.2%) CRCs
were MSI, 90/303 (29.7%) were CIMP-positive, and 21/191
(10.9%) harbored a somatic V600E mutation in the BRAF gene.
As expected, the CIMP-positive phenotype was more frequently
associated with MSI and the presence of BRAF V600E mutation
(22.3% vs. 2.3%, p,0.0001 for the MSI phenotype, and 31% vs.
1.5%, p,0.0001 for the BRAF V600E mutation).
Diagnostic significance of methylation markers in CRC
The mean methylation levels for each gene in primary CRC
tissues were: 23.8% for SEPT9, 50.5% for TWIST1, 44.9% for
IGFBP3, 50.2% for GAS7, 36.5% for ALX4, and 35.3% for
miR137. As shown in Figure 1, methylation levels of each gene
were significantly higher in CRC versus normal mucosa from
healthy subjects (p,0.0001 to p,0.0005 for all comparisons).
These results demonstrate the cancer-specificity for hypermethyla-
tion of these genes and establish a rationale for their exploitation as
potential diagnostic biomarkers for CRC, considering that all 6
markers demonstrated hypermethylation in all stages of CRCs
(Figure 2).
In order to assess the performance of each methylation marker
individually for CRC diagnosis, methylation results were analyzed
as a categorical variable. Accordingly, each gene was classified as
methylated when mean methylation levels were higher than 7.1%
for SEPT9, 35.7% for TWIST, 27.5% for IGFBP3, 53.5% for
GAS7, 28.5% for ALX4, and 11.9% for miR137. Based upon
these analyses, the most frequently methylated markers in CRC
tissues were the miR-137 gene (302/344, 87.7%), followed by
IGFBP3 (289/348, 83%), TWIST1 (269/356, 75.6%), SEPT9
(244/346, 70.5%), ALX4 (214/350, 61.1%), and GAS7 (164/378,
43.3%). To further assess whether a combination of markers
would further enhance the diagnostic accuracy of the assay, we
analyzed combination marker panels and found that the miR137+
IGFBP3 combination yielded an diagnostic accuracy of 86%,
followed by TWIST1+IGFBP3 (82.7%) and TWIST1+miR137
(78.5%). Furthermore, we found that the combination of miR137+
IGFBP3+TWIST1 methylation had the highest diagnostic accu-
racy, 92%, as shown in Table 1.
Clinicopathological features associated with methylation
biomarkers
We next investigated the relationship between various clinico-
pathological and molecular features and their association with
aberrant methylation of all six genes analyzed in this study. The
clinicopathological variables included age, gender, TNM staging
and tumor location, and the molecular factors included the MMR
status, CIMP phenotype and the BRAF mutational status. Tumor
location and TNM stages did not associate with the methylation
status of any of the gene markers. Curiously, SEPT9 methylation
was significantly associated with male gender (p,0.05; Table S3).
When methylation was analyzed as a continuous variable, we
observed a trend for higher methylation of TWIST1, IGFBP3,
ALX4, and GAS7 (p,0.05) and older patients with CRC;
however, we did not find a positive correlation between normal
colonic mucosa methylation in these genes and age in healthy
individuals (Figures 3 & 4).
Figure 4. Correlation between colon mucosa methylation and age of healthy controls. linear regression analysis comparing tumor
methylation of sept9 (a), twist1 (b), igfbp3 (c), alx4 (d), gas7 (e) and mir137 (f) vs age of the healthy control patients (years).
doi:10.1371/journal.pone.0104285.g004
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With regards to molecular associations, TWIST1 methylation
levels were higher in MSS compared to MSI CRCs (51% vs
40.3%; p,0.05) (Table 2). Methylation of four genes, ALX4,
IGFBP3, GAS7, and miR137, was significantly correlated with
CIMP-positive tumors (p,0.001). Furthermore, as shown in
Table 2, CRCs with ALX4 and IGFBP3 methylation were more
frequently associated with a somatic BRAF V600E mutation
(13.5% vs. 1.8%, p,0.05 for ALX4, and 12.4% vs. 0%, p,0.05
for IGBFP3).
Aberrant hypermethylation of genes and its influence on
CRC patient prognosis
The median follow-up for the series of 425 patients included in
this study was 1268 days (3.4 years; range 0–2204 days). At the end
of the follow-up period, 169 patients had died (39.7%), and the
median follow-up for this group was 6716513 days (1.861.4
years). Information regarding the cause of death was available in
99 patients; 67.7% (67/99) died due to complications of tumor
progression, 18.2% (18/99) died due to complications of
chemotherapy, and 14.1% (14/99) succumbed to death from
other causes, including post-operative complications. Tumor
recurrence was observed in 116/370 patients (31.3%), with a
median time duration of 6446448 days (1.761.2 years) post-
surgery.
To determine the prognostic significance of the methylation
status for each gene, all CRCs were categorized into two groups
based on their methylation levels (high versus low), and the dose–
response relationship between the degree of methylation and
event-free survival was examined by ROC curve analysis. Overall,
high levels of methylation of the GAS7 (prognosis cut-off
value = 52.62%; high-methylation: 43.3%, low-methylation:
56.7%; x2 p = 0.03) and ALX4 genes (prognosis cut-off val-
ue = 25.8%; high-methylation: 67.1%, low-methylation: 32.9%; x2
p = 0.005) associated with poor DFS in CRC patients (data not
shown). In contrast, low levels of IGFBP3 methylation demon-
strated an association with significantly worse DFS according to
unadjusted analysis (prognosis cut-off value = 53.1%; high-
methylation: 30.9%, low-methylation: 69.1%; x2 p = 0.01; Figur-
es 5A and B). Following multivariate Cox regression analysis
where multiple variables were analyzed, only low levels of
IGFBP3 methylation emerged as an independent risk factor for
poor DFS in stage II and III CRC patients (HR=0.49, 95% CI:
0.28–0.85, p,0.01). Furthermore, the methylation status of the
IGFBP3 gene was the only statistically significant risk factor for
stage II CRC, after adjustment for other prognostic factors such as
age, adjuvant 5-FU (5-Fluorouracil) chemotherapy or MSI status
(HR=0.28, 95% CI: 0.12–0.70, p = 0.006; Table 3).
Aberrant gene hypermethylation and its influence on
patient survival following chemotherapy treatment
Chemotherapeutic treatment was given to 257/425 patients
(60.5%), mainly using 5FU+leucovorin (236; 91.8% of patients).
Among the entire cohort, 315 patients (74.1%) had either a stage
II or III disease, and 155 (49.2%) of these received 5FU-based
adjuvant chemotherapy. Only 9 stage II and III patients received
other chemotherapeutic treatments, and were excluded from
further analysis. After a median follow-up of 1221 days (3.3 years),
92 (31.2%) patients with stage II and III showed tumor recurrence,
and by the end of the follow-up period, 101 (34.2%) patients from
these groups had died.
Adjuvant chemotherapy provided a significant improvement in
OS in stage II and III CRC patients compared to patients who did
not receive chemotherapy (chemotherapy: 49.1%, no-chemother-
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apy: 50.9%; x2 p= 0.0001). These differences in OS were also
present in multivariate analysis which controlled for age, gender,
lymph node metastasis, MMR, and CIMP phenotype status
(HR=0.55, 95% CI: 0.36–0.85, p = 0.007).
Interestingly, among all 6 methylation markers investigated,
only IGFBP3 methylation levels were predictive of the response to
5FU-based chemotherapy. According to our results, patients with
low IGFBP3 methylation levels had longer OS (p= 0.0007) and
DFS (p= 0.05) when they received chemotherapy. Conversely, in
patients with high IGFBP3 methylation, adjuvant chemotherapy
did not improve OS (p= 0.4) or DFS (p= 0.3; Figure 5C and D).
Using multivariate Cox regression analysis (Table 4), in patients
with low-IGFBP3 methylation, adjuvant chemotherapy indepen-
dently predicted better OS (HR=0.49, 95%CI: 0.29–0.80,
p = 0.004); however, it did not significantly influence DFS
(p = 0.08). On the other hand, MMR status was the only variable
that independently predicted OS (p= 0.05) and DFS (p = 0.04) in
patients with high IGFBP3 methylation (Table 4). In the patient
cohort treated with 5-FU adjuvant chemotherapy, IGFBP3
methylation status did not independently predict OS and DFS.
In contrast, DFS was positively affected by IGFBP3 methylation
status in patients who did not receive adjuvant chemotherapy
(HR=0.41, 95%CI: 0.18–0.91, p = 0.02).
Discussion
In the recent years, a number of promising gene methylation-
based diagnostic biomarkers including SEPT9, TWIST 1,
IGFBP3, GAS7, ALX4, and miR137 have been proposed for
the early detection of colorectal neoplasia. However, the majority
of these markers have been confined to initial small-scale discovery
Figure 5. Relationship between igfbp3 methylation and prognostic and predictive response in stage ii and iii crc patients. (a)
Disease-free survival of patients with stage ii and iii crc, according to igfbp3 methylation status (high methylation, n = 73, (30.3%) low methylation,
n = 168, (69.7%). (b) Disease-free survival of patients with stage ii disease, according to igfbp3 methylation (high methylation, n = 45, (32.4%); low
methylation, n = 94, (67.6%). (c) Disease-free survival of patients with stage ii and iii disease, in high igfbp3 methylation tumors based on adjuvant
chemotherapy (chemotherapy, n = 20, (22.5%); no chemotherapy, n = 69, (77.5%). (d) Disease-free survival of patients with stage ii and iii disease, in
low igfbp3 methylation tumors according to adjuvant chemotherapy (Chemotherapyc n = 83, (52.7%); NO Chemotherapy, n = 74, (47.2%).
doi:10.1371/journal.pone.0104285.g005
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studies, and have not been developed into clinical practice as they
have not been systematically validated in large, independent
cohorts of CRC patients. In view of this gap in knowledge, we
designed this study to confirm the diagnostic potential of these
biomarkers, and to ascertain their prognostic and predictive values
in CRC. In addition, we were interested in examining the
associations between aberrant hypermethylation of these genes
and clinicopathological features by analyzing a large, well-
characterized, population-based cohort of CRC patients.
Based on our quantitative methylation analysis, all six genes
interrogated fulfilled the criteria for potential clinical use as
diagnostic biomarkers of CRC. These criteria included: a) the
methylation of each gene occurred in a tumor-specific manner; b)
the methylation levels of each gene in neoplastic tissues were
significantly higher than in normal colonic mucosa; and c) none of
the genes showed an age-dependent increase in DNA methylation
in normal colonic mucosa [30,31]. Methylation levels of each gene
allowed us to classify colorectal tissues as normal or neoplastic.
Among all markers investigated, IGFBP3 and miR137 methyla-
tion levels showed the highest diagnostic accuracy as individual
gene markers for the identification of primary CRCs (83%
and 78.3%, respectively). This diagnostic accuracy was
further improved by combining the methylation status of two
gene markers; in particular, the methylation status of
IGFBP3+TWIST1 or IGFBP3+miR137 had the highest accura-
Table 3. Multivariate analysis of disease-free survival based on IGFBP3 promoter methylation in stage II and III CRC patients.
Stage II and III CRC Patients Hazard Ratios (HR) 95% CI P-value
Tumor size (T3/4 vs. T1/2) 1.479 0.46–4.69 0.5
Lymph Node metastasis (Positive vs. Negative) 1.605 1.01–2.54 0.04
MMR Status (MSI vs. MSS) 0.739 0.26–2.06 0.5
Differentiation Grade (Poor vs. Well/Moderate) 0.86 0.34–2.16 0.7
IGFBP3 Methylation (High vs. Low) 0.479 0.26–0.87 0.01
Stage II CRC Patients Hazard Ratios (HR) 95% CI P-value
Age (. Median vs. , Median) 0.774 0.36–1.70 0.5
Serosal invasion (Yes vs. No) 1.485 0.62–3.51 0.3
Chemotherapy (Yes vs. No) 0.61 0.27–1.36 0.2
MMR Status (MSI vs. MSS) 0.612 0.13–2.73 0.5
Differentiation Grade (Poor vs. Well/Moderate) 0.548 0.20–1.47 0.2
IGFBP3 Methylation (High vs. Low) 0.28 0.12–0.70 0.006
CI: Confidence interval; mmr: mismatch repair; msi: microsatellite instability; mss: microsatellite stable.
doi:10.1371/journal.pone.0104285.t003
Table 4. Multivariate analysis of disease-free survival and overall survival in stage ii and iii crc patients and igfbp3 promoter
methylation status.
DFS OS
HR 95%CI P-value HR 95%CI P-value
High-IGFBP3 Methylation Group
Age (.65, vs. ,65) 1.697 0.66–4.35 0.3 1.218 0.49–3.02 0.7
Gender (Male vs. Female) 1.802 0.91–3.55 0.08 1.457 0.77–2.74 0.2
MMR Status (MSI vs MSS) 0.371 0.14–0.98 0.04 0.391 0.14–1.02 0.05
Lymph Node Metastasis (positive vs. negative) 0.666 0.31–1.41 0.3 0.98 0.59–1.66 0.9
CIMP (positive vs. negative) 1.141 0.57–2.26 0.7 1.443 0.74–2.82 0.3
Adjuvant Chemotherapy (yes vs. no) 0.721 0.35–1.47 0.4 0.52 0.25–1.05 0.07
Low-IGFBP3 Methylation Group
Age (.65 vs. ,65) 0.995 0.45–2.16 0.9 1.135 0.66–1.92 0.6
Gender (Male vs. Female) 0.897 0.6–1.34 0.6 0.901 0.6–1.34 0.6
MMR Status (MSI vs. MSS) 0.65 0.29–1.33 0.2 0.593 0.27–1.26 0.2
Lymph Node Metastasis (positive vs. negative) 1.372 0.91–2.05 0.1 1.429 1.05–1.93 0.02
CIMP (positive vs. negative) 0.828 0.48–1.41 0.5 0.844 0.49–1.43 0.5
Adjuvant Chemotherapy (yes vs. no) 0.655 0.41–1.05 0.08 0.489 0.29–0.80 0.004
DFS: Disease-free survival; os: overall survival; hr: hazard ratio; ci : confidence interval; mmr: mismatch repair; msi: microsatellite instability; mss: microsatellite stable;
cimp: cpg island methylator phenotype.
doi:10.1371/journal.pone.0104285.t004
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cy values of 86% and 82.7% respectively, with sensitivity and
specificity values . 80%.
We investigated the molecular features associated with tumor
methylation levels of these genes. This was of particular interest as
molecular classification based on MSI and CIMP status has
become increasingly important [32] for its prognostic [33,34,35]
and predictive role in CRC patients [7,34,36]. In this study, four
of the six genes were positively associated with the CIMP
phenotype (ALX4, IGFBP3, GAS7, and miR137). Furthermore,
a positive correlation between BRAF V600E mutation and
methylation of the ALX4 and IGFBP3 genes was associated with
CIMP-high in CRC [37,38]. As expected, methylation of the
ALX4 and IGFBP3 genes was associated with the presence of the
BRAF gene mutation. TWIST1 methylation levels were higher in
patients with MMR-proficient tumors compared to MSI tumors;
however, in our cohort, only a small proportion of CRCs were
MMR-deficient (5%), and the correlations between MMR status
and methylation markers may have been lost when analyzing the
group as a whole.
In stage II and III CRC patients who have undergone
potentially curative resection, prognosis depends on disease
recurrence, which is primarily associated with distant metastasis.
In addition, the benefit from adjuvant chemotherapy, especially
for stage II CRC patients has remained an area of controversy and
chemotherapeutic resistance remains a major problem in these
patients. Therefore, the discovery of novel prognostic and
predictive biomarkers that can help identify stage II and III
patients that are at high risk of recurrence and metastasis, may
improve the current strategy for CRC patient stratification and
therapy management. To the best of our knowledge, no previous
study has examined the relationship between methylation of the
SEPT9, IGFBP3, TWIST1, GAS7, ALX4, and miR137 genes
with prognosis in patients with CRC, as well as the ability of these
biomarkers to predict response to 5-FU-based adjuvant chemo-
therapy. Based upon our results in this large, well-characterized
population-based cohort, stage II and III CRC patients with low
levels of IGFBP3 promoter methylation had poorer OS and DFS
compared to those with high levels of DNA hypermethylation.
With regards to response to chemotherapy, when 5-FU based
adjuvant chemotherapy was administered to stage II and III CRC
patients, only those patients with low levels of IGFBP3-methylated
tumors were positively affected, resulting in longer DFS and OS
times, indicating that the benefit of chemotherapy was limited to
this group of CRC patients. Curiously, this effect of IGFBP3
methylation was independent of CIMP status. Nevertheless it is
important to point out that although IGFBP3 methylation status
emerged as the only independent factor that predicted poor DFS
probability among stage II CRC patients, additional independent
clinical studies are required to prove that IGFBP3 methylation
levels in CRC could represent a potential routine test for
Figure 6. Comparison between methylation levels within igfbp3 promoter in crc tissues. (a) Schematic overview of the insulin-like grown
factor binding protein 3 (igfbp3) gene. exons are represented by blue boxes, introns with blue lines, and the promoter region by blue dashed lines.
the igfbp3 gene has one cytosine-phosphate-guanine (cpg) island at in the promoter region and exon1 underscoring the potential of modulating
gene expression by means of cpg hypermethylation, and this is represented by a green box. we performed two different assays covering both cpgs
islands (indicated by green arrows) using two quantitative methods: pyrosequencing and qmsp in order to correlate methylation levels of these two
locations. (b) Linear regression analysis comparing igfbp3 methylation levels by pyrosequencing (% methylation) in 348 patient samples and qmsp
(pmr) assays in crc tissues (n = 197).
doi:10.1371/journal.pone.0104285.g006
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prognostication of CRC patients, and in improving the manage-
ment of patients with localized disease in combination with current
clinicopathological and molecular tools.
Other studies have observed a relationship between high levels
of IGFBP3 methylation and poor clinical outcome in lung and
ovarian cancers [39,40], and more recently in CRC patients [27].
Discrepant reports using methylation markers may be due to the
use of different methodologies and the analysis of different
sequence locations within CpG Islands. In this study, we used
bisulfite pyrosequencing for methylation analysis, which is a
reliable quantitative approach for robust DNA methylation
analysis compared to the conventional Methylation Specific
PCR (MSP), which lacks the quantification provided by bisulfate
pyrosequencing [27,39,40]. In addition, to further ensure the
accuracy of our methylation results, we also conducted a
quantitative-MSP (qMSP) analysis within the CpG island region
previously studied in CRC [41]. As shown in Figure 6, we
confirmed that our bisulfite pyrosequencing methylation results
were positively correlated to the results obtained within the CpG
island region previously studied [27,39,40].
Although there are some differences between this study and
previously published studies, we believe this work is more robust
and comprehensive, as ours employs the largest patient cohort, is
population-based, and includes a control group of non-treated
CRC patients for comparison. The biological role and timing of
IGFBP3 methylation in CRC is poorly understood; however,
recent in vitro studies have reported that methylation-induced
silencing of IGFBP3 may lead to significant resistance to cisplatin
treatment in lung cancer [42,43]. Conversely, it is also possible
that this event is merely a consequence of CIMP, and IGFBP3
methylation consequently serves as a surrogate marker of this
phenotype and may be an important determinant of poor
responses to 5-FU-based adjuvant chemotherapy in CRC, as
previously shown by our laboratory [7]. It is very likely that
IGFBP3 methylation alone may not provide requisite sensitivity
and specificity for a clinically viable test, and inclusion of
additional biomarkers may further improve the clinical signifi-
cance of this biomarker. Although work from our laboratory and
other laboratories have previously provided data for the functional
role of miR-137 and IGFBP3 methylation in colorectal cancer
[21,44], additional in-vitro and in-vivo studies in this regard may
further facilitate in gathering a better understanding of the
biological roles of these biomarkers in colorectal carcinogenesis.
In summary, this study performed a comprehensive analysis of a
large, population-based CRC cohort and clearly highlighted the
potential roles of the methylation status of miR137 and IGFBP3
as diagnostic biomarkers in CRC patients. In addition, our data
revealed that IGFBP3 promoter methylation serves as an
independent prognostic biomarker in stage II and III colorectal
cancer patients. Our results also suggest that stage II&III CRC
patients with high levels of IGFBP3 methylation do not benefit
from adjuvant 5FU-based chemotherapy.
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